• Ariad Pharmaceuticals Inc., of Cambridge, Mass., reported its first revenue from cancer drug Iclusig (ponatinib), which was approved in December for use in adults with chronic myelogenous leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia that is resistant or intolerant to prior tyrosine kinase inhibitor therapy. Net sales totaled $6.4 million for the quarter ending March 31. Ariad posted a net loss for the quarter of $64.7 million, or 36 cents per share, a narrower loss than the 38 cents per share expected by analysts. The company ended the quarter with about $398.3 million on its balance sheet. Shares of Ariad (NASDAQ:ARIA) closed Tuesday at $17.55, up 20 cents. (See BioWorld Today, Dec. 17, 2012.)
To read more on related topics, click on one of the words below.